CHRS · Coherus Oncology, Inc. · Analyst Estimates
Substantial doubt about the company's ability to continue as a going concern.
“After considering these plans and the guidance within ASC 205-40, we concluded that substantial doubt about our ability to continue as a going concern had not been alleviated for the one-year period following the issuance of these condensed consolidated financial statements. Our expected future operating losses and negative cash flows, together with our need for additional funding to support planned operations, raise substantial doubt about our ability to continue as a going concern for a period of one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Coherus Oncology, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians. An EPS figure names its accounting basis, GAAP or Non-GAAP, where the capture records one, and compares only with the company's EPS on that basis; without one, the basis is not recorded.
Captured 2026-11-18 05:06 UTC · Publication dates shown per estimate · 4 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.90
|
-0.90
|
-0.90
|
1
|
-0.87
|
-0.86
|
-0.86
|
-0.86
|
0
|
1
|
0
|
1
|
|
Revenue
USD
Publication date not stated |
56.34M
|
56.71M
|
57.04M
|
5
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.62
|
-0.62
|
-0.62
|
1
|
-0.65
|
-0.63
|
-0.63
|
-0.63
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
78.02M
|
87.50M
|
109.70M
|
6
|
— | — | — | — | — | — | — | — |